{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Cedars-Sinai
Cedars-Sinai
  • Sign In
  • Live Activities
  • Internal Series
  • On-Demand Activities
  • CE Planning Process
  • Calendar
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Use My Cedars Login
Login with my CloudCME™ account
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Forgot Your Password?

Login Tips: 
PLEASE CREATE AN ACCOUNT IF:

• You have never attended a Cedars-Sinai CE activity
• OR You are a NEW member of the Cedars-Sinai Medical Staff since August 2023

If you do NOT meet either of the criteria above, please DO NOT CREATE AN ACCOUNT:

• If you do not know which email address is used for your account, please contact the Cedars-Sinai Office of CME.
• Accounts for existing Cedars-Sinai Medical Staff (prior to August 2023) use the primary email on file with the Medical Staff Office.

For ALL USERS: If you do not have the password for your account, click the "Forgot Your Password?" link.

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • ATC
  • BSN
  • CCC-SLP
  • CCLS
  • CPhT
  • CRNA
  • CRT
  • DC
  • DDS
  • DMD
  • DNAP
  • DNP
  • DO
  • DPM
  • LCGC
  • LCSW
  • LVN
  • MBBCh
  • MBBS
  • MD
  • MD, PhD
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • NP
  • OT
  • Other
  • OTR/L
  • PA
  • PharmD
  • PhD
  • PsyD
  • PT
  • RD
  • RN
  • RN, BSN
  • RPh
  • RRT
  • RT
  • RVT
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

2025 Research Updates in Lymphoma


2025 Research Updates in Lymphoma Banner

  • Overview
  • Register
  • Faculty
  • Schedule
Add to Calendar 2025 Research Updates in Lymphoma 10/18/2025 7:30:00 AM 10/19/2025 3:00:00 PM America/Los_Angeles For More Details: https://cedars.cloud-cme.com/lymphomacme Description: This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, "How I Treat" sessions will address questions of sequencing therapies and patients selection. The scientific sessions will prese... Cedars-Sinai Advanced Health Science Pavilion Educational Center and Online false MM/DD/YYYY


Date & Location
Saturday, October 18, 2025, 7:30 AM - Sunday, October 19, 2025, 3:00 PM PST, Cedars-Sinai Advanced Health Science Pavilion Educational Center and Online, Los Angeles, CA

Target Audience
Specialties - Hematology, Imaging, Internal Medicine, Oncology, Pathology & Laboratory Medicine, Radiation Oncology, Radiology, Surgery
Professions - Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)

Overview
This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, "How I Treat" sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.

Objectives
  1. Recognize the utility of molecular testing in the classification and treatment of lymphoma
  2. Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma
  3. Describe new treatments under development including bi specific antibodies and CART therapies
  4. Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

Registration

In-Person Fees
In-Person: Healthcare Professional Fee - $0.00
In-Person: Industry Attendee (No Exhibit Booth) - $550.00

Virtual Fees
Virtual: Healthcare Professional Fee - $0.00
Virtual: Industry Attendee (No Exhibit Booth) - $550.00


Accreditation

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 10.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician AMA Attendance
Attendance credit will be provided to other healthcare professionals upon the fulfillment of attendance requirements. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.  

Credits
AMA PRA Category 1 Credit(s)™ (MD, DO) (10.00 hours), ANCC (10.00 hours), IPCE (10.00 hours), Non-Physician AMA Attendance (10.00 hours)


Keywords: LIVEAMAANCCIPCEHybrid (In-person and On-line)



Mitigation of Relevant Financial Relationships


Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.



Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Faculty Photos
Hitomi Hosoya, MD, PhD
Stanford University
Course Director, Faculty
Nothing to disclose
Faculty Photos
Akil Merchant, MD
Cedars-Sinai
Course Director, Faculty
Advisor-Novartis AG|Advisor-Pfizer, Inc.|Advisor-Morphosys|Consultant-Genmab|Consultant-Abbvie|Consultant-Bristol-Myers Squibb
Leslie Ballas, MD
Faculty
Advisor-Blue earth (Relationship has ended)|Other: Editor-UroToday|Advisor-Pfizer, Inc. (Relationship has ended)|Royalties or Patent Beneficiary-UpToDate
Faculty Photos
Elizabeth Brem, MD
UCI School of Medicine
Faculty
Consultant-BeOne|Speaker-AstraZeneca|Advisor-AstraZeneca|Advisor-Genentech, Inc.|Advisor-Regeneron|Advisor-ADC Therapeutics|Advisor-Caribou Biosciences (Relationship has ended)|Advisor-Posieda (Relationship has ended)|Advisor-Incyte (Relationship has ended)|Advisor-Bristol-Myers Squibb (Relationship has ended)|Speaker-Bristol-Myers Squibb|Speaker-AbbVie, Genmab|PrincipalNamedInvestigator-Regeneron
Elizabeth Lihua Budde, MD, PhD
Faculty
Faculty Photos
Yvonne Chen, PhD
Microbiology, Immunology & Molecular Genetics, UCLA
Faculty
StockPrivate-ImmPACT Bio (Relationship has ended)|StockPrivate-Catamaran Bio (Relationship has ended)|StockPrivate-Notch Therapeutics (Relationship has ended)|StockPrivate-Pluto Immunotherapeutics|StockPrivate-Sonoma Biotherapeutics|StockPrivate-Waypoint Bio|Stock Options or Shareholder-Prime Medicine|Consultant-Novartis AG (Relationship has ended)|StockPrivate-AffyImmune (Relationship has ended)|StockPrivate-Lyell Immunopharma|StockPrivate-Harton
Faculty Photos
Anthony R Colombo, PhD
USC
Faculty
Nothing to disclose
Faculty Photos
Sean R Corcoran , MD, PhD
Cedars-Sinai
Faculty
Stock Options or Shareholder-CRISPR Therapeutics
Faculty Photos
Justin Darrah, MD
Cedars-Sinai
Faculty
Advisor-Genmab (Relationship has ended)
Sven de Vos, MD, PhD
Faculty
Faculty Photos
Juliane Gust, MD, PhD
Dr. (Ms.)
Faculty
Faculty Photos
Sarah Larson, MD
UCLA Health
Faculty
Faculty Photos
Joseph C. Lownik, MD
Cedars-Sinai
Faculty
Nothing to disclose
Faculty Photos
Matthew G. Mei, MD
City of Hope
Faculty
Consultant-SeaGen (Relationship has ended)|Consultant-ADC Therapeutics (Relationship has ended)|Speaker-SeaGen (Relationship has ended)|Consultant-Synthekine (Relationship has ended)
Faculty Photos
David R. Oveisi, MD
Cedars Sinai Medical Center
Faculty
Giri Ramsingh , MD
Faculty
Faculty Photos
Lisa M Rimsza, MD
The University of Arizona
Faculty
Speaker-Roche
David Russler-Germain, MD, PhD
WashU Medicine
Faculty
Advisor-Genentech, Inc. (Relationship has ended)|Consultant-Regeneron|Consultant-Tempus|Advisor-Ipsen (Relationship has ended)|Consultant-AbbVie (Relationship has ended)
Parag Sanghvi, MD
UC San Diego School of Medicine
Faculty
Faculty Photos
Joshua Sasine, MD, PhD
Cedars-Sinai
Faculty
Nothing to disclose
Faculty Photos
Joe Schroers-Martin, MD
Stanford Medicine
Faculty
Consultant-Pierre-Fabre|Advisor-Incyte (Relationship has ended)|Consultant-Navya
Faculty Photos
Hrishikesh Srinagesh, MD
Stanford Medicine
Faculty
Other: Honoraria-Sobi (Relationship has ended)|Other: Honoraria-Takeda (Relationship has ended)
Faculty Photos
Brian Sworder, MD, PhD
University of California, Irvine
Faculty
Consultant-Foresight Diagnostics|Stock Options or Shareholder-Cargo Therapeutics|Stock Options or Shareholder-Allogene Therapeutics|Consultant-ADC Therapeutics
Kevin Tang, MD
Cedars Sinai Medical Center
Faculty
Nothing to disclose
John Timmerman, MD
Faculty
Mina Xu, MD
Yale University School of Medicine
Faculty
Nothing to disclose
Alyssa Maskell, MSN
Cedars Sinai
Planner
Nothing to disclose

Saturday, October 18, 2025
Registration Check In and Exhibits
7:30AM - 8:00AM

Welcome and Introduction
8:00AM - 8:10AM
 
Hot Topics in Clinical Lymphoma – Part I

Session Chair: Sarah Larson, MD
Frontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates
8:10AM - 8:35AM
Joe Schroers-Martin, MD

Novel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates
8:35AM - 9:00AM
Matthew G. Mei, MD

Advances in CAR-T Cell Therapy for B-Cell Lymphomas: Earlier Lines & New Indications (2L DLBCL, FL, MCL, MZL)
9:00AM - 9:25AM
Sven de Vos, MD, PhD

Break and Exhibits
9:25AM - 9:45AM

 
Hot Topics in Clinical Lymphoma – Part II

Session Chair: Lihua Elizabeth Budde
Bispecific Antibodies in DLBCL and Follicular Lymphoma: Current Successes and Future Combinations
9:45AM - 10:10AM
Elizabeth Lihua Budde, MD, PhD

Breakthroughs in CTCL and Other Cutaneous Lymphoma
10:10AM - 10:35AM

Emerging Therapies for Relapsed/Refractory Follicular Lymphoma
10:35AM - 11:00AM
John Timmerman, MD

 
Lightning Round

Lightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)
11:00AM - 11:30AM

 
Lunch and Networking

Lunch and Exhibits
11:30AM - 12:15PM

 
Keynote & Basic Science Insights

Session Chair: Akil Merchant, MD
KEYNOTE ADDRESS: Spatial Profiling in Lymphoma: Unveiling the Tumor Microenvironment and Cellular Interactions
12:15PM - 1:00PM
Mina Xu, MD

Microenvironment in Hodgkin Lymphoma
1:00PM - 1:20PM
Anthony R Colombo, PhD
Molecular Determinants of Sensitivity to Polatuzmab
1:20PM - 1:40PM
Sean R Corcoran , MD, PhD
Metabolic Profiling and Modulation of the Lymphoma Microenvironment
1:40PM - 2:00PM
Akil Merchant, MD

Break and Exhibits
2:00PM - 2:20PM
 
Next Generation Diagnostics and Biomarkers

Session Chair: Joseph C. Lownik, MD
Lymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling
2:20PM - 2:50PM
Lisa M Rimsza, MD

Developing an Automated Multiplex IF for Diagnostic/Biomarker Use in Lymphoma
2:50PM - 3:10PM
Joseph C. Lownik, MD

Role of ct DNA in Lymphoma
3:10PM - 3:30PM
Brian Sworder, MD, PhD
Geriatric Assessment of Patients with Lymphoma: Clinical Trial and Routine Practice
3:30PM - 3:50PM
Elizabeth Brem, MD

Hidden Opponents: The DLBCL Microenvironment
3:50PM - 4:10PM
David Russler-Germain, MD, PhD

Adjourn
4:10PM - 4:15PM

 
Networking Reception

Networking Reception
4:15PM - 5:30PM

Sunday, October 19, 2025
Registration Check In and Exhibits
7:30AM - 8:00AM

 
CAR-T Cell Therapy: Managing Complex Toxicities

Session Chair: Hitomi Hosoya, MD, PhD
Mechanisms of Neurotoxicity with IEC and Bispecific Therapies
8:00AM - 8:20AM
Juliane Gust, MD, PhD

IEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management
8:20AM - 8:40AM
Hrishikesh Srinagesh, MD
Prophylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches
8:40AM - 9:00AM
Joshua Sasine, MD, PhD
Secondary and T-cell Malignancies after CART
9:00AM - 9:20AM
Hitomi Hosoya, MD, PhD

Break and Exhibits
9:20AM - 9:35AM
 
Clinical Debate--What is the optimal Bridging Strategy for CAR-T therapy

Session Chair: Justin Darrah, MD
Intro: Why bridging?
9:35AM - 9:40AM
Justin Darrah, MD

Role of Bispecifics as Bridging
9:40AM - 9:50AM
Sarah Larson, MD

Radiation as Bridging
9:50AM - 10:00AM
Parag Sanghvi, MD

Optimal Chemotherapy for Bridging
10:00AM - 10:10AM
David R. Oveisi, MD
Debate and Discussion
10:10AM - 10:35AM

 
Next Generation Cellular Therapies for Lymphoma and Beyond

Session Chair: Yvonne Chen, PhD
Dual Targeting CAR T: Lymphoma
10:35AM - 10:55AM

Novel CART for Solid Tumors
10:55AM - 11:15AM
Yvonne Chen, PhD

Innovations in TIL Therapy
11:15AM - 11:35AM
Giri Ramsingh , MD

Novel ROR1 Targeting CART for Multiple Cancer Types
11:35AM - 11:55AM
Kevin Tang, MD

Adjourn and Pick Up Boxed Lunch
11:55AM - 12:00PM


CE Disclosure Form  | CE Application  | Privacy  |  Cedars-Sinai CME Homepage

Contact Us: [email protected]

        

© 2025 Cedars-Sinai. All Rights Reserved. A 501(c)(3) non-profit organization.